EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
Rhea-AI Summary
EyePoint (Nasdaq: EYPT) will report fourth-quarter and full-year 2025 results and host a conference call and live webcast at 8:30 a.m. ET on March 4, 2026. The event will include a review of financial results and recent corporate developments.
According to the company, registration is required for the audio conference and a live webcast plus replay will be available on the company's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – EYPT
On the day this news was published, EYPT gained 4.16%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $59M to the company's valuation, bringing the market cap to $1.47B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
With EYPT down 0.12%, peers show a mixed picture: names like QURE and OCS are up, while PRAX, URGN, and UPB trade lower. Momentum scanner peers also split between up and down moves, suggesting stock-specific trading rather than a coordinated sector reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Investor conferences | Neutral | -0.1% | Participation in four March 2026 investor conferences with webcast access. |
| Feb 18 | Executive appointment | Positive | -3.7% | Appointment of Chief Commercial Officer to lead DURAVYU Phase 3 launch readiness. |
| Feb 17 | Inducement grants | Neutral | +15.2% | Nasdaq Rule 5635(c)(4) option inducement awards totaling 143,000 shares. |
| Feb 05 | Conference appearance | Neutral | +3.2% | CFO fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026. |
| Jan 16 | Inducement grants | Neutral | -4.8% | Inducement stock options for new employees under Nasdaq Rule 5635(c)(4). |
Recent news, often neutral or positive, has frequently seen divergent price reactions, with several sizable moves following routine corporate updates.
Over the last few months, EyePoint has issued a series of corporate updates, including investor conference participation on Feb 24, 2026, a new Chief Commercial Officer appointment on Feb 18, 2026, and multiple inducement option grants in January–February 2026. These were accompanied by both sharp gains (e.g., +15.22% on Feb 17) and notable declines (e.g., -4.8% on Jan 16). Today’s earnings date notice fits into a pattern of frequent, operationally focused disclosures without a consistent price reaction direction.
Market Pulse Summary
This announcement schedules EyePoint’s fourth quarter and full-year 2025 earnings call for March 4, 2026 at 8:30 a.m. ET, providing a clear catalyst date for detailed financial and corporate updates. In recent months, routine corporate news has at times led to sizable moves, so the upcoming call and webcast will be key for understanding revenue trends, cash updates previously signaled in the 8-K, and progress on strategic initiatives.
AI-generated analysis. Not financial advice.
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments.
To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A webcast replay will also be available on the Company website at the conclusion of the call.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Green Room Communications
Direct: 850-384-2833
EyePointMedia@grcomms.com
FAQ
When will EyePoint (EYPT) report Q4 and full-year 2025 results?
How can investors access the EyePoint (EYPT) March 4, 2026 conference call?
Will EyePoint (EYPT) provide a replay of the March 4, 2026 webcast?
What topics will EyePoint (EYPT) cover during the March 4, 2026 call?
Where is the EyePoint (EYPT) webcast hosted for the March 4, 2026 event?
